PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    2.
    发明申请
    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 有权
    PRMT1用于目标癌基因治疗和诊断

    公开(公告)号:US20110160293A1

    公开(公告)日:2011-06-30

    申请号:US13060672

    申请日:2009-08-25

    Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

    Abstract translation: 本文描述了用于诊断发展中的癌症,特别是膀胱癌,胃癌,结肠直肠癌,乳腺癌,食管癌,肺癌,淋巴瘤,胰腺癌和睾丸癌的易感性的客观方法。 在一个实施方案中,诊断方法包括确定PRMT1基因的表达水平。 本发明还提供筛选用于治疗PRMT1相关疾病例如癌症的治疗剂的方法,例如癌症。 膀胱癌,胃癌,结肠直肠癌,乳腺癌,食管癌,肺癌,淋巴瘤,胰腺癌和睾丸癌。 本发明还提供了抑制细胞生长和治疗或减轻PRMT1相关疾病症状的方法。 本发明还涉及包括双链分子和编码它们的载体以及包含它们的组合物的产品。

    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    4.
    发明公开
    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 有权
    PRMT1用于癌症治疗和诊断的靶基因

    公开(公告)号:EP2329044A1

    公开(公告)日:2011-06-08

    申请号:EP09809533.4

    申请日:2009-08-25

    Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

    Abstract translation: 本文描述了用于诊断癌症发生倾向的客观方法,特别是膀胱癌,胃癌,结肠直肠癌,乳腺癌,食道癌,肺癌,淋巴瘤,胰腺癌和睾丸癌。 在一个实施方案中,诊断方法涉及确定PRMT1基因的表达水平。 本发明进一步提供了筛选可用于治疗PRMT1相关疾病例如癌症的治疗剂的方法。 膀胱癌,胃癌,结肠直肠癌,乳腺癌,食道癌,肺癌,淋巴瘤,胰腺癌和睾丸癌。 本发明还提供了抑制细胞生长和治疗或缓解PRMT1相关疾病症状的方法。 本发明的特征还在于产物,包括双链分子和编码它们的载体以及包含它们的组合物。

Patent Agency Ranking